Detalhe da pesquisa
1.
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
J Extracell Vesicles
; 11(3): e12192, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289114